GlaxoSmithKline created a vaccine to protect against four strains of the flu virus. Prior to its advent, vaccines protected against only three strains. More comprehensive viral protection is important because providers never know which strain will predominate in a given year. The vaccine is called Fluarix Quadrilivalent (Fluarix). Recently, the FDA approved Fluarix for shipment to health care providers, and the largest order for the vaccine came from the U.S. Centers for Disease Control and Prevention (CDC). The CDC ordered 4 million doses for initial distribution to local and state health care providers.
Read more here.